Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the
company's Board of Directors has authorized the repurchase of up to
$3.0 billion of the company's common stock through December 2010.
Purchases may be made in the open market or in privately
negotiated transactions from time to time, as determined by Gilead's
management and in accordance with the requirements of the Securities
and Exchange Commission. As of September 30, 2007, Gilead had
approximately 928,864,666 shares of common stock outstanding.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of unmet
medical need. The company's mission is to advance the care of patients
suffering from life-threatening diseases worldwide. Headquartered in
Foster City, California, Gilead has operations in North America,
Europe and Australia.
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors. The reader is
cautioned not to rely on these forward-looking statements. These and
other risks are described in detail in the Gilead Annual Report on
Form 10-K for the year ended December 31, 2006 and its Quarterly
Reports on Form 10-Q for the first and second quarters of 2007 as
filed with the U.S. Securities and Exchange Commission. All
forward-looking statements are based on information currently
available to Gilead and Gilead assumes no obligation to update any
such forward-looking statements.
For more information on Gilead Sciences, please visit the
company's website at www.gilead.com or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
